TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35039242

Group type: EXPERIMENTAL
Intervention: Nocturnal Polyuria Index >0.33 (NPI33)
Number of subjects: 10190

Group type: EXPERIMENTAL
Intervention: Nocturnal urine production >90 ml/h (NUP90)
Number of subjects: 10190

Group type: EXPERIMENTAL
Intervention: Idiopathic NP (NPI33)
Number of subjects: 10190

Group type: EXPERIMENTAL
Intervention: Idiopathic NP (NUP90)
Number of subjects: 10190
Study: 35039278

Group type: EXPERIMENTAL
Intervention: Wysa digital mental health intervention
Number of subjects: 61
Study: 35039279

Group type: EXPERIMENTAL
Intervention: Digital life coaching (DLC) for 16 weeks starting on day -5 before SCT.
Number of subjects: 15
Study: 35039291

Group type: EXPERIMENTAL
Intervention: Camu Camu (CC) supplementation
Number of subjects: 22
Study: 35039916

Group type: EXPERIMENTAL
Intervention: Anal tape intervention applied to the anus during days 15-28
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control period (days 0-14)
Number of subjects: 20
Study: 35039952

Group type: EXPERIMENTAL
Intervention: Sulindac 150 mg twice daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Observation group (non-randomized control)
Number of subjects: 50
Study: 35040037

Group type: EXPERIMENTAL
Intervention: Capaciflector
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Capaciflector during CPET
Number of subjects: 70

Group type: COMPARATOR
Intervention: Capaciflector at rest
Number of subjects: 70
Study: 35040156

Group type: EXPERIMENTAL
Intervention: Adalimumab (s.c. doses according to package insert)
Number of subjects: 83
Study: 35040160

Group type: EXPERIMENTAL
Intervention: Serum ZFP concentration in patients with AN
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Serum LBP and i-FABP levels in patients with AN
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: BMI, age, and INR as predictors of serum ZFP in patients with AN
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Eating disorder symptoms and gastrointestinal complaints in patients with AN
Number of subjects: 25
Study: 35040485

Group type: EXPERIMENTAL
Intervention: Remote monitoring (RM) with alert transmissions
Number of subjects: 1271

Group type: COMPARATOR
Intervention: No alert transmissions during RM
Number of subjects: 1271

Group type: EXPERIMENTAL
Intervention: Last alert-triggered transmission before death
Number of subjects: 1271

Group type: EXPERIMENTAL
Intervention: Last scheduled transmission before death
Number of subjects: 1271

Group type: EXPERIMENTAL
Intervention: Time from last alert-triggered transmission to death
Number of subjects: 1271
Study: 35040753

Group type: EXPERIMENTAL
Intervention: Core stability (abdominal contraction) during exercises (dynamic movement in seated position and march-in-place exercise)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Core stability (abdominal contraction)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Post-stroke patients
Number of subjects: 55
Study: 35040945

Group type: EXPERIMENTAL
Intervention: Breath-holding test (BHT)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 6 minute walk test (6MWT)
Number of subjects: 72
Study: 35040961

Group type: EXPERIMENTAL
Intervention: Higher functional connectivity in pre-SMA network
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Higher SMA network segregation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lower functional connectivity in pre-SMA network
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: No association of transition type with SMA functional connectivity
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Exploratory analysis
Number of subjects: 120
Study: 35041128

Group type: EXPERIMENTAL
Intervention: Surgery for patients with pneumo-hematoceles of 5 cm or persistent lesions of 3 cm
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Pneumo-hematocele diameter
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Ruptured pneumo-hematoceles
Number of subjects: 37
Study: 35041147

Group type: EXPERIMENTAL
Intervention: FFR+QFR- lesions
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: FFR-QFR+ lesions
Number of subjects: 195

Group type: COMPARATOR
Intervention: FFR
Number of subjects: 195
Study: 35041449

Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CTA) with subendocardial attenuation analysis
Number of subjects: 735

Group type: COMPARATOR
Intervention: Coronary computed tomography angiography (CTA)
Number of subjects: 735
Study: 35041482

Group type: EXPERIMENTAL
Intervention: Afternoon procedures (TAVR or SAVR)
Number of subjects: 5586

Group type: COMPARATOR
Intervention: Morning procedures (TAVR or SAVR)
Number of subjects: 5586
Study: 35041493

Group type: EXPERIMENTAL
Intervention: Imatinib (400 mg once daily) plus binimetinib (30 mg twice daily)
Number of subjects: 42
Study: 35041672

Group type: EXPERIMENTAL
Intervention: CL Detect Rapid Test on skin slit samples
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: CL Detect Rapid Test on dental broach samples
Number of subjects: 165

Group type: COMPARATOR
Intervention: Microscopy (routine method)
Number of subjects: 165

Group type: COMPARATOR
Intervention: PCR (reference method)
Number of subjects: 165
Study: 35041751

Group type: EXPERIMENTAL
Intervention: Testosterone treatment (duration: 12 months)
Number of subjects: 0
Study: 35042068

Group type: EXPERIMENTAL
Intervention: Durvalumab 1500 mg every four weeks
Number of subjects: 867
Study: 35042070

Group type: EXPERIMENTAL
Intervention: Adapted pyrexia management algorithm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historical COMBI-AD control
Number of subjects: 0
Study: 35042101

Group type: EXPERIMENTAL
Intervention: HCV care facilitation
Number of subjects: 113

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 113
Study: 35042449

Group type: EXPERIMENTAL
Intervention: RFA with MESS
Number of subjects: 139
Study: 35042460

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Pelvic radiotherapy treatment
Number of subjects: 200
Study: 35042534

Group type: EXPERIMENTAL
Intervention: Plasma SNORD33 signature
Number of subjects: 0
Study: 35042555

Group type: EXPERIMENTAL
Intervention: Anti-CCP+ individuals with high antibody levels
Number of subjects: 6780

Group type: EXPERIMENTAL
Intervention: Anti-CCP+ individuals with hand pain
Number of subjects: 6780

Group type: EXPERIMENTAL
Intervention: Anti-CCP+ individuals with foot pain
Number of subjects: 6780

Group type: EXPERIMENTAL
Intervention: Low-level anti-CCP+ individuals without pain in hands or feet
Number of subjects: 6780

Group type: COMPARATOR
Intervention: Anti-CCP- individuals with one-year follow-up
Number of subjects: 6780

Group type: COMPARATOR
Intervention: Anti-CCP- individuals with knee pain
Number of subjects: 6780
Study: 35042560

Group type: EXPERIMENTAL
Intervention: TXA 500 mg two times daily for 28 days
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo two times daily for 28 days
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: TXA 500 mg
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 35042563

Group type: EXPERIMENTAL
Intervention: Laparoscopically guided transversus abdominis plane block (LTAP) with levobupivacaine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Local wound analgesia with levobupivacaine
Number of subjects: 46
Study: 35042564

Group type: EXPERIMENTAL
Intervention: Outcome imagery exercise
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Process imagery exercise
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Combined condition (outcome and process imagery)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control condition (neither exercise)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 260
Study: 35042704

Group type: EXPERIMENTAL
Intervention: Universal screening for HCV and HIV in the emergency room
Number of subjects: 6350

Group type: EXPERIMENTAL
Intervention: Opt-out option for testing
Number of subjects: 6350

Group type: EXPERIMENTAL
Intervention: Organizational reasons for not testing
Number of subjects: 6350

Group type: EXPERIMENTAL
Intervention: HCV-HIV coinfection
Number of subjects: 6350
Study: 35042709

Group type: EXPERIMENTAL
Intervention: Intensified health education (I)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Intensified health education and SMS/telephonic tracing (I)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Intensified health education, SMS/telephonic tracing and transport reimbursement (I)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Pre-implementation phase (C)
Number of subjects: 320
Study: 35043194

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35043241

Group type: EXPERIMENTAL
Intervention: Roadsaver™ dual-layer micromesh stent
Number of subjects: 1967
Study: 35043384

Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 52
Study: 35043682

Group type: EXPERIMENTAL
Intervention: Subsequent treatment for mCRC patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes using the EuroQol 5-level, 5-dimensional questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes using the Brief Fatigue Inventory
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes using a modified version of the ACCEPTance by the Patients of their Treatment
Number of subjects: 0
Study: 35043686

Group type: EXPERIMENTAL
Intervention: Combination of pembrolizumab and laser interstitial thermal therapy
Number of subjects: 0
Study: 35043689

Group type: EXPERIMENTAL
Intervention: Bystander cardiopulmonary resuscitation (CPR)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Total cardiopulmonary resuscitation time
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Resuscitation-associated injury
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Time-critical injuries
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Age comparison of patients with resuscitation injury
Number of subjects: 104
Study: 35043976

Group type: EXPERIMENTAL
Intervention: VB124 (MCT4 inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of MCT4 inhibition and anti-PD-1 immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Higher MCT4 expression in tumor tissues
Number of subjects: 0
Study: 35044445

Group type: EXPERIMENTAL
Intervention: Archetypal analysis (AA) applied to ON VFs
Number of subjects: 456

Group type: COMPARATOR
Intervention: Control group VFs analyzed using AA
Number of subjects: 456
Study: 35045174

Group type: EXPERIMENTAL
Intervention: Gut microbiome of adults with T1D
Number of subjects: 74

Group type: COMPARATOR
Intervention: Gut microbiome of healthy control subjects
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Functional analysis of gut microbiome
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Microbial taxa and metabolic pathways
Number of subjects: 74
Study: 35045184

Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Hyperglycemia and higher insulin doses
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM) adjusted for suPAR levels
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM) mediated by suPAR
Number of subjects: 686
Study: 35045358

Group type: EXPERIMENTAL
Intervention: Intravenous CAR T cells administered intrapleurally (10-186 mL) via image-guided techniques (intracavitary or intratumoral)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intravenous CAR T cells administered intrapleurally
Number of subjects: 31
Study: 35045389

Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Sedentary behavior (SB)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Parental hypoglycemia worry
Number of subjects: 25
Study: 35045421

Group type: EXPERIMENTAL
Intervention: Osilodrostat (Isturisa®)
Number of subjects: 0
Study: 35045559

Group type: EXPERIMENTAL
Intervention: 100,000 IU cholecalciferol every 6 to 8 weeks
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 50,000 IU cholecalciferol every 4 to 5 weeks
Number of subjects: 43
Study: 35045732

Group type: EXPERIMENTAL
Intervention: Resting distal coronary to aortic pressure ratio (Pd/Pa)
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Fractional flow reserve (FFR)
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: FFR and Pd/Pa discrepancy
Number of subjects: 517
Study: 35045748

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35045815

Group type: EXPERIMENTAL
Intervention: Various palliative interventions for ESCC including chemotherapy, radiation therapy (with and without chemotherapy), and esophageal stenting with self-expandable metallic stents.
Number of subjects: 0
Study: 35045843

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 1388

Group type: EXPERIMENTAL
Intervention: Poor physical performance (lower SPPB values)
Number of subjects: 1388

Group type: EXPERIMENTAL
Intervention: Preserved physical performance (higher SPPB values)
Number of subjects: 1388

Group type: EXPERIMENTAL
Intervention: SPPB values
Number of subjects: 1388

Group type: EXPERIMENTAL
Intervention: Clinical features and SPPB in multivariable model
Number of subjects: 1388
Study: 35045877

Group type: EXPERIMENTAL
Intervention: Nurse-led, person-centered anticipatory care planning (ACP) intervention
Number of subjects: 12
Study: 35045989

Group type: EXPERIMENTAL
Intervention: Remdesivir (200 mg IV on day 0, followed by 100 mg IV daily for 10 days)
Number of subjects: 1282

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 1282
Study: 35046010

Group type: EXPERIMENTAL
Intervention: Qualitative semistructured interviews conducted 6-16 months after patient death
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Experiences of family members during pandemic restrictions
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Solidarity among clinical staff
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Suggestions for improving end-of-life care
Number of subjects: 28
Study: 35046056

Group type: EXPERIMENTAL
Intervention: VIP152 monotherapy (30 mg, once-weekly intravenous infusion)
Number of subjects: 37
Study: 35046059

Group type: EXPERIMENTAL
Intervention: Afatinib and Pembrolizumab
Number of subjects: 29
Study: 35046060

Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-DTPA-CHX-A"-SC16 at 500 μCi
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-DTPA-CHX-A"-SC16 at 750 μCi
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-DTPA-CHX-A"-SC16 at 250 μCi
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-DTPA-CHX-A"-SC16
Number of subjects: 18
Study: 35046063

Group type: EXPERIMENTAL
Intervention: Idecabtagene vicleucel
Number of subjects: 100
Study: 35046093

Group type: EXPERIMENTAL
Intervention: CD therapeutic dietary intervention (CD-TDI)
Number of subjects: 102
Study: 35046124

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cardiac power output (CPO)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Stroke work (SW)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Oxygen delivery
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Microcirculatory markers (lactate and venous-to-arterial carbon dioxide difference)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Inflammatory and cardiac biomarkers
Number of subjects: 42
Study: 35046132

Group type: EXPERIMENTAL
Intervention: Steroid-sparing immunosuppressive protocol
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Bone histomorphometry
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control of mineral metabolism
Number of subjects: 97
Study: 35046672

Group type: EXPERIMENTAL
Intervention: KPC-producing strains
Number of subjects: 36
Study: 35046747

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (five 30-minute weekly sessions)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (sitting quietly during the experimental sessions)
Number of subjects: 108
Study: 35046880

Group type: EXPERIMENTAL
Intervention: Oral mannitol (18 g per day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (dextrose)
Number of subjects: 22
Study: 35046943

Group type: EXPERIMENTAL
Intervention: First-line chemoradiotherapy combined with PD-1 blockade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High percentages of PD-L1
Number of subjects: 0
Study: 35047011

Group type: EXPERIMENTAL
Intervention: Stochastic gradient boosting model
Number of subjects: 394
Study: 35047784

Group type: EXPERIMENTAL
Intervention: Pharmacological therapy after revascularisation
Number of subjects: 10000000

Group type: EXPERIMENTAL
Intervention: Subgroup analysis by gender and disease severity
Number of subjects: 10000000
Study: 35047801

Group type: EXPERIMENTAL
Intervention: Prostate artery embolization (PAE)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 164
Study: 35048355

Group type: EXPERIMENTAL
Intervention: Individualized dosing of pemetrexed
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard dosing of pemetrexed
Number of subjects: 0
Study: 35048715

Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 204

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 204
Study: 35048809

Group type: EXPERIMENTAL
Intervention: Liposomal Oxaliplatin Suspension for Injection (MBP-426)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxaliplatin (OxPt)
Number of subjects: 0
Study: 35049375

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35049381

Group type: EXPERIMENTAL
Intervention: History of sexual assault
Number of subjects: 0

Group type: COMPARATOR
Intervention: No history of sexual assault
Number of subjects: 0
Study: 35050485

Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg
Number of subjects: 327

Group type: COMPARATOR
Intervention: Secukinumab 300 mg
Number of subjects: 327
Study: 35050743

Group type: EXPERIMENTAL
Intervention: Plasma T790M testing
Number of subjects: 63

Group type: COMPARATOR
Intervention: Tissue T790M testing
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Osimertinib treatment
Number of subjects: 63
Study: 35050753

Group type: EXPERIMENTAL
Intervention: Molecular-based recommended therapy (MBRT)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Targeted therapies provided in the setting of a clinical trial or through compassionate use programs
Number of subjects: 50

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 50
Study: 35050780

Group type: EXPERIMENTAL
Intervention: Genomic SVI (gSVI) classifier
Number of subjects: 15889

Group type: EXPERIMENTAL
Intervention: gSVI combined with MSKCC nomogram
Number of subjects: 15889

Group type: COMPARATOR
Intervention: Established nomograms (Partin Tables and MSKCC)
Number of subjects: 15889
Study: 35050961

Group type: EXPERIMENTAL
Intervention: Interdisciplinary multimodal pain therapy
Number of subjects: 41
Study: 35051703

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (cCRT) with trametinib (1.5 mg)
Number of subjects: 15
Study: 35051737

Group type: EXPERIMENTAL
Intervention: OSA
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: OHS
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: ORSH
Number of subjects: 82
Study: 35051831

Group type: EXPERIMENTAL
Intervention: Major bleeding (gastrointestinal, intracranial, hematoma, genitourinary, retroperitoneal, other sites) during anticoagulation
Number of subjects: 2244

Group type: EXPERIMENTAL
Intervention: Major bleeding in the first 30 days after VTE
Number of subjects: 2244
Study: 35051950

Group type: EXPERIMENTAL
Intervention: Severe intraoperative hyperglycemia (SIH) with blood glucose concentration (BGC) ≥180 mg/dL
Number of subjects: 514

Group type: COMPARATOR
Intervention: No severe intraoperative hyperglycemia (BGC <180 mg/dL)
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Intraoperative BGC >140 mg/dL
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Elevated preoperative glycated hemoglobin (HbA1c) concentration
Number of subjects: 514
Study: 35056370

Group type: EXPERIMENTAL
Intervention: Bispectral Index Monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observer Rating Scale
Number of subjects: 0
Study: 35057743

Group type: EXPERIMENTAL
Intervention: Lognormal shared frailty models with restricted cubic splines and non-proportional hazards (LSF-NPH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inverse Gaussian shared frailty model with proportional hazard (ISF-PH)
Number of subjects: 0
Study: 35057807

Group type: EXPERIMENTAL
Intervention: Moderate physical activity (at least 2 times/week to every day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lower exercise levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate physical activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High physical activity in diabetic individuals
Number of subjects: 0
Study: 35058267

Group type: EXPERIMENTAL
Intervention: Markerless tumour tracking (MTT)
Number of subjects: 30
Study: 35058275

Group type: EXPERIMENTAL
Intervention: Non-curative ESD followed by surgical treatment (n=126)
Number of subjects: 604

Group type: COMPARATOR
Intervention: Non-curative ESD followed by endoscopic follow-up (n=81)
Number of subjects: 604
Study: 35058326

Group type: EXPERIMENTAL
Intervention: isatuximab (anti-CD38 monoclonal antibody) + cemiplimab (anti-PD-1 monoclonal antibody)
Number of subjects: 44
Study: 35058336

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 22
Study: 35058354

Group type: EXPERIMENTAL
Intervention: Donor-derived cell-free DNA fraction (dd-cfDNA[%]) in plasma
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Genome-wide gene expression in biopsies
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Microarray-based Molecular Microscope Diagnostic System
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Histology assessments following Banff guidelines
Number of subjects: 289
Study: 35058690

Group type: EXPERIMENTAL
Intervention: Group 1 ventilators (higher PTP 300)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Group 2 ventilators (lower PTP 300)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bench study with nine ventilators
Number of subjects: 10
Study: 35058694

Group type: COMPARATOR
Intervention: Asymptomatic ICAD
Number of subjects: 573

Group type: COMPARATOR
Intervention: Symptomatic ICAD
Number of subjects: 573
Study: 35058784

Group type: EXPERIMENTAL
Intervention: Physiologically-Based Kinetics (PBK) model for homosalate
Number of subjects: 0
Study: 35058882

Group type: EXPERIMENTAL
Intervention: Glucocorticoid receptor antagonism with mifepristone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0